Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

NCT00883480 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

153

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Docetaxel
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Erlotinib

Sponsor

Spanish Lung Cancer Group